Cytori Therapeutics Inc (NASDAQ:CYTX) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Friday, May 12th.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
A number of other brokerages have also issued reports on CYTX. B. Riley reiterated a “buy” rating and issued a $2.30 price target on shares of Cytori Therapeutics in a report on Wednesday, May 10th. Maxim Group set a $10.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Saturday, March 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.45.
Cytori Therapeutics (NASDAQ:CYTX) traded down 3.92% during trading on Friday, hitting $0.98. The stock had a trading volume of 401,332 shares. Cytori Therapeutics has a 52-week low of $0.90 and a 52-week high of $2.29. The firm’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.41. The company’s market cap is $31.83 million.
Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.05. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $2.32 million. During the same quarter last year, the business earned ($0.03) earnings per share. Cytori Therapeutics’s revenue was down 53.8% compared to the same quarter last year. Analysts predict that Cytori Therapeutics will post ($0.90) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Cytori Therapeutics Inc (CYTX) Rating Increased to Hold at Zacks Investment Research” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/06/17/cytori-therapeutics-inc-cytx-upgraded-by-zacks-investment-research-to-hold-updated-updated-updated.html.
An institutional investor recently raised its position in Cytori Therapeutics stock. Vanguard Group Inc. boosted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 19.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 336,651 shares of the biotechnology company’s stock after buying an additional 55,948 shares during the period. Vanguard Group Inc. owned about 1.43% of Cytori Therapeutics worth $539,000 at the end of the most recent quarter. Institutional investors own 8.70% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.